Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

AI-guided personalized T cell receptor transgenic T cell therapy against cancer

Ziel

"Personalised T cell therapy has shown remarkable success in cancer therapy, however the antigens that T cells recognize to kill tumor cells are dependent on the individual tumor, T cell receptor (TCR) profile and antigen presentation machinery. AI-TreatCancer will leverage predicTCR, a proprietary AI-guided classifier that identifies tumor-killing TCRs from patient samples, decreasing the time to identify therapeutic TCRs from 3-4 months to under 2 weeks.
In the ERC Advanced Grant (ERC-2023-ADG #101141901 — Characterizing and harnessing tumor-reactive T cells in the brain; “CENTRIC-BRAIN”), predicTCR was extensively validated, including resolving the target antigens of many TCRs. Following discussions with the regulator we identified key regulatory compliance obstacles that must be resolved prior to implementing predicTCR in a first-in-human, AI-guided personalised transgenic T cell therapy trial - the first step to securing investment for market entry.
Firstly we will develop robust quality control metrics that automatically identify compromised patient samples before analysis, preventing false-positive TCR identification that could lead to ineffective therapies. Secondly AI-TreatCancer will establish regulatory compliance for the use of predicTCR in selecting tumor-targeting TCRs for a clinical trial.
The project's high-gain potential extends beyond immediate clinical application. Success would establish a new regulatory framework for AI-assisted companion diagnostics in cell therapies, creating a template for future innovations. A compliant predicTCR would enable systematic TCR discovery, including in rare cancers currently excluded from therapeutic development, and potentially identify cross-entity shared tumor-reactive TCRs for “off-the-shelf” cell therapies. Furthermore, the comprehensive quality control pipeline would set industry standards for single-cell sequencing in clinical applications, benefiting the broader precision medicine field.


"

Wissenschaftliches Gebiet (EuroSciVoc)

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) ERC-2025-POC

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Gastgebende Einrichtung

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Netto-EU-Beitrag
€ 150 000,00
Adresse
IM NEUENHEIMER FELD 280
69120 Heidelberg
Deutschland
Region
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Aktivitätstyp
Research Organisations
Links
Gesamtkosten
Keine Daten

Begünstigte (1)